Even if it's not a huge purchase, we think it was good to see that William Brighton, the Independent Director of ...
As at December 2024, Regulus Therapeutics had cash of US$76m and no debt. Looking at the last year, the company burnt through US$42m. That means it had a cash runway of around 22 months as of December ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results